Formulary Chapter 1: Gastro-intestinal system - Full Chapter
|
01.06.01 |
Bulk-forming laxatives |
|
|
Ispaghula Husk (Granules)
|
Formulary
|
Follow Optimise Rx recommendation on which brand to choose
Adequate fluid intake is important to prevent obstruction (6-8 cups per day) and should not be taken immediatley before bed
Unsuitable for frail patients who are likely to drink less than daily required volume of fluid
Fluid thickens on standing so should be taken as soon as possible after mixing
Time to effect is approximately 48-72 hours
|
Key |
|
Restricted Drug |
|
Unlicensed |
|
Link to adult BNF
|
|
Link to children's BNF
|
|
Link to SPCs
|
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine |
|
Cancer Drugs Fund |
|
NHS England |
|
Homecare |
|
ICB |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
Status |
Description |
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications |
|
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry. |
|
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. |
|
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist. |
|
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only |
|
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information. |
|
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use. |
|
Check Notes as varies across the area |
|
|